Posts Tagged ‘FDA’

Is Nanox another Theranos?

Posted on: September 18th, 2020 by admin 1 Comment

At the beginning of 2020, we highlighted the story of Theranos, manufacturer of a “revolutionary” blood testing system that was supposedly able […]

Professor and Entrepreneur

Posted on: September 11th, 2020 by admin No Comments

Twenty years ago, I published a commentary entitled “The professor as entrepreneur” in which I reflected on my decade as an academic […]

Breast Screening and Radiation

Posted on: August 14th, 2020 by admin

One of the reasons why some women are reluctant to subject themselves to an annual mammogram is a concern that […]

DBT vs FFDM – Again

Posted on: July 31st, 2020 by admin

In a recent paper published in JAMA Network Open, Kathryn Lowry (seen right) asked the question: Does screening performance of digital breast […]

The Next Unicorn

Posted on: July 24th, 2020 by admin 2 Comments

In the business world, a “unicorn” is the term used to indicate that a privately held startup company has a […]

DBT + AI = Progress

Posted on: November 22nd, 2019 by admin

Despite a recent report calling into question the benefits of digital breast tomosynthesis (DBT) – sometimes called 3D mammography – as a […]

Does 3D Mammography Save More Lives?

Posted on: October 25th, 2019 by admin 2 Comments

A week ago, USA Today published an article written by Liz Szabo (seen right) with the provocative headline, “Massive marketing muscle pushes […]

HHUS versus ABUS

Posted on: July 19th, 2019 by admin 2 Comments

Fifteen years ago, Peter Dempsey wrote a fascinating article on the history of breast ultrasound that appeared in the Journal […]

The Evidence is Growing

Posted on: March 29th, 2019 by admin 1 Comment

The introduction of full-field digital mammography (FFDM) as a replacement for plane-film analogue mammography started over two decades ago. Shortly […]

Language of Breast Density

Posted on: March 1st, 2019 by admin 2 Comments

Over the years, we have written multiple articles about breast density, including its reduction, legislation, diagnostic challenges and workflow optimization. One may reasonably ask: Why this […]